首页 > 最新文献

Journal of Basic and Clinical Physiology and Pharmacology最新文献

英文 中文
The prospective record-breaking obesity drug tirzepatide raises concerns about affordability. 有望破纪录的肥胖药物替西帕肽引发了人们对其可负担性的担忧。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-06-19 eCollection Date: 2023-07-01 DOI: 10.1515/jbcpp-2023-0129
Rajmohan Seetharaman, Swarnima Pandit, Shirish Shashikant Joshi
{"title":"The prospective record-breaking obesity drug tirzepatide raises concerns about affordability.","authors":"Rajmohan Seetharaman, Swarnima Pandit, Shirish Shashikant Joshi","doi":"10.1515/jbcpp-2023-0129","DOIUrl":"10.1515/jbcpp-2023-0129","url":null,"abstract":"","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 4","pages":"549-550"},"PeriodicalIF":0.0,"publicationDate":"2023-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9889363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A drug utilisation pattern in non-dialysis patients of diabetic nephropathy in a government-run tertiary care hospital in South-Asia. 南亚一家政府三级医院非透析糖尿病肾病患者的药物使用模式
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 DOI: 10.1515/jbcpp-2023-0003
Rajmohan Seetharaman, Manjari Advani, Smita Mali, Sudhir Pawar

Objectives: The objective of the present study was to evaluate the Drug utilisation pattern in patients of diabetic nephropathy (stage 1-4) in a tertiary care hospital in South-Asia.

Methods: A cross-sectional observational study was conducted in the nephrology out-patient-department of a tertiary care hospital in South-Asia. WHO core prescribing, dispensing, and patient care indicators were evaluated, and adverse drug reactions (ADRs) encountered by the patients were analysed for causality, severity, preventability, and outcome.

Results: The most commonly prescribed antidiabetics in diabetic nephropathy patients were insulin (17.42%), followed by metformin (4.66%). Current drugs of choice SGLT-2 inhibitors were prescribed in a lesser frequency than expected. Loop diuretics and calcium channel blockers (CCBs) were the preferred antihypertensives. The use of ACE inhibitors (1.26%) and ARBs (3.45%) for hypertension was restricted to Stage 1 and 2 nephropathy. The patients were on 6.47 drugs on average. 30.70% of drugs were prescribed by generic names, 59.07% of the drugs were prescribed from the national essential drugs list and 34.03% of the prescribed drugs were supplied by the hospital. CTCAE grade 1 (68.60%) and grade 2 (22.09%) ADR severity was the highest.

Conclusions: Prescribing patterns in patients of diabetic nephropathy were adapted from relevant medical evidence, affordability and availability of the drugs. Generic prescribing, availability of drugs and ADR preventability in the hospital have a broad scope for improvement.

目的:本研究的目的是评估南亚一家三级医院糖尿病肾病(1-4期)患者的药物使用模式。方法:在南亚某三级医院肾内科门诊进行横断面观察研究。评估了世卫组织的核心处方、配药和患者护理指标,并分析了患者遇到的药物不良反应(adr)的因果关系、严重程度、可预防性和结果。结果:糖尿病肾病患者最常使用的降糖药是胰岛素(17.42%),其次是二甲双胍(4.66%)。目前选择的SGLT-2抑制剂的处方频率低于预期。循环利尿剂和钙通道阻滞剂(CCBs)是首选的抗高血压药物。高血压患者使用ACE抑制剂(1.26%)和arb(3.45%)仅限于1期和2期肾病。患者平均使用6.47种药物。30.70%的药品采用通用名处方,59.07%的药品采用国家基本药物目录,34.03%的药品由医院供应。CTCAE 1级(68.60%)和2级(22.09%)ADR严重程度最高。结论:糖尿病肾病患者的处方模式应根据相关医学证据、药物的可负担性和可获得性进行调整。医院的非专利处方、药品可得性和药品不良反应的可预防性有很大的改进空间。
{"title":"A drug utilisation pattern in non-dialysis patients of diabetic nephropathy in a government-run tertiary care hospital in South-Asia.","authors":"Rajmohan Seetharaman,&nbsp;Manjari Advani,&nbsp;Smita Mali,&nbsp;Sudhir Pawar","doi":"10.1515/jbcpp-2023-0003","DOIUrl":"https://doi.org/10.1515/jbcpp-2023-0003","url":null,"abstract":"<p><strong>Objectives: </strong>The objective of the present study was to evaluate the Drug utilisation pattern in patients of diabetic nephropathy (stage 1-4) in a tertiary care hospital in South-Asia.</p><p><strong>Methods: </strong>A cross-sectional observational study was conducted in the nephrology out-patient-department of a tertiary care hospital in South-Asia. WHO core prescribing, dispensing, and patient care indicators were evaluated, and adverse drug reactions (ADRs) encountered by the patients were analysed for causality, severity, preventability, and outcome.</p><p><strong>Results: </strong>The most commonly prescribed antidiabetics in diabetic nephropathy patients were insulin (17.42%), followed by metformin (4.66%). Current drugs of choice SGLT-2 inhibitors were prescribed in a lesser frequency than expected. Loop diuretics and calcium channel blockers (CCBs) were the preferred antihypertensives. The use of ACE inhibitors (1.26%) and ARBs (3.45%) for hypertension was restricted to Stage 1 and 2 nephropathy. The patients were on 6.47 drugs on average. 30.70% of drugs were prescribed by generic names, 59.07% of the drugs were prescribed from the national essential drugs list and 34.03% of the prescribed drugs were supplied by the hospital. CTCAE grade 1 (68.60%) and grade 2 (22.09%) ADR severity was the highest.</p><p><strong>Conclusions: </strong>Prescribing patterns in patients of diabetic nephropathy were adapted from relevant medical evidence, affordability and availability of the drugs. Generic prescribing, availability of drugs and ADR preventability in the hospital have a broad scope for improvement.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 3","pages":"371-381"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9826553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Pathophysiological effects of cadmium(II) on human health-a critical review. 镉(II)对人体健康的病理生理影响——综述
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 DOI: 10.1515/jbcpp-2021-0173
Kaustav Bhattacharyya, Debrup Sen, Payel Laskar, Tania Saha, Gautam Kundu, Alok Ghosh Chaudhuri, Subhadeep Ganguly

Cadmium(II) is an omnipresent environmental toxicant emitted from various industrial sources and by anthropogenic sources such as smoking. Cadmium(II) enters our body through various sources including contaminated food and drinks and from active or passive smoking. It spares no organs in our body and the calamities it invites include primarily nephrotoxicity, osteotoxicity, teratogenicity, endocrine disruption, hepatotoxicity and carcinogenicity above all. It brings about a bolt from the blue in the cellular biochemistry by generating reactive oxygen species (ROS), disrupting the factors involved in the repair of DNA lesions and many other toxic nuisances otherwise by modulating the cell signalling machinery and acting as a potent carcinogen above all. In this review, we have tried to decipher some of the mechanisms played by cadmium(II) in exhibiting its toxic effects on various system of our body.

镉(II)是一种无处不在的环境毒物,由各种工业来源和人为来源(如吸烟)排放。镉(II)通过各种途径进入我们的身体,包括受污染的食物和饮料,以及主动或被动吸烟。它不放过我们身体的任何器官,它引起的灾难主要包括肾毒性、骨毒性、致畸性、内分泌紊乱、肝毒性和致癌性。它通过产生活性氧(ROS),通过调节细胞信号机制,破坏修复DNA损伤和许多其他有毒有害物质的因素,在细胞生物化学中带来了一个晴天霹雳,首先是作为一种强致癌物。在这篇综述中,我们试图破译镉(II)在显示其对我们身体各系统的毒性作用中发挥的一些机制。
{"title":"Pathophysiological effects of cadmium(II) on human health-a critical review.","authors":"Kaustav Bhattacharyya,&nbsp;Debrup Sen,&nbsp;Payel Laskar,&nbsp;Tania Saha,&nbsp;Gautam Kundu,&nbsp;Alok Ghosh Chaudhuri,&nbsp;Subhadeep Ganguly","doi":"10.1515/jbcpp-2021-0173","DOIUrl":"https://doi.org/10.1515/jbcpp-2021-0173","url":null,"abstract":"<p><p>Cadmium(II) is an omnipresent environmental toxicant emitted from various industrial sources and by anthropogenic sources such as smoking. Cadmium(II) enters our body through various sources including contaminated food and drinks and from active or passive smoking. It spares no organs in our body and the calamities it invites include primarily nephrotoxicity, osteotoxicity, teratogenicity, endocrine disruption, hepatotoxicity and carcinogenicity above all. It brings about a bolt from the blue in the cellular biochemistry by generating reactive oxygen species (ROS), disrupting the factors involved in the repair of DNA lesions and many other toxic nuisances otherwise by modulating the cell signalling machinery and acting as a potent carcinogen above all. In this review, we have tried to decipher some of the mechanisms played by cadmium(II) in exhibiting its toxic effects on various system of our body.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 3","pages":"249-261"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9833951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib. 布鲁顿激酶抑制剂(BTKi)在加速慢性淋巴细胞白血病(a- cll)中的作用:阿卡拉布替尼成功应答的一例
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 DOI: 10.1515/jbcpp-2023-0051
Gioacchino Catania, Rita Tavarozzi, Giacomo Maria Pini, Tiziana Borra, Carolina Gandolfo, Giulia Zacchi, Daniela Pietrasanta, Federico Monaco, Manuela Zanni, Maddalena Lettieri, Paolo Rivela, Francesco Zallio, Marco Ladetto

Objectives: The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the clinical history of patients with chronic lymphocytic leukemia (CLL) in both naïve and relapsed/refractory settings. "Accelerated" chronic lymphocytic leukemia (a-CLL) is a relatively rare form of CLL representing less than 1 % of all CLL cases. a-CLL patients usually have a more aggressive course and a reduced overall survival was reported with conventional chemo-immunotherapy approaches.

Methods: The role of Bruton Tyrosine Kinase-inhibitor, ibrutinib, in a-CLL is well established with encouraging preliminary results.

Results: We report a case of a-CLL-treated first-line with second-generation BTKi, acalabrutinib with a prompt clinical response. As known, it is the first literature report on acalabrutinib in a-CLL highlighting the role of second-generation BTKi also in this high-risk setting.

Conclusions: Target therapies (Bruton Kinase inhibitors and Bcl2 inhibitors) have improved the therapeutic landscape of CLL. The availability of therapeutic targets requires greater diagnostic accuracy to choose the most appropriate therapy for each patient.

目的:布鲁顿酪氨酸激酶(BTK)抑制剂的使用改变了naïve和复发/难治性慢性淋巴细胞白血病(CLL)患者的临床病史。“加速型”慢性淋巴细胞白血病(a-CLL)是一种相对罕见的慢性淋巴细胞白血病,占所有慢性淋巴细胞白血病病例的比例不到1%。据报道,a- cll患者通常具有更积极的病程,采用传统的化学免疫治疗方法总生存率降低。方法:布鲁顿酪氨酸激酶抑制剂依鲁替尼在a-CLL中的作用得到了很好的确立,并取得了令人鼓舞的初步结果。结果:我们报告了一例使用第二代BTKi阿卡拉布替尼一线治疗的a- cll患者,临床反应迅速。众所周知,这是第一篇关于阿卡拉布替尼治疗a-CLL的文献报道,强调了第二代BTKi在这种高风险环境中的作用。结论:靶向治疗(布鲁顿激酶抑制剂和Bcl2抑制剂)改善了CLL的治疗前景。治疗靶点的可用性要求更高的诊断准确性,以便为每位患者选择最合适的治疗方法。
{"title":"The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib.","authors":"Gioacchino Catania,&nbsp;Rita Tavarozzi,&nbsp;Giacomo Maria Pini,&nbsp;Tiziana Borra,&nbsp;Carolina Gandolfo,&nbsp;Giulia Zacchi,&nbsp;Daniela Pietrasanta,&nbsp;Federico Monaco,&nbsp;Manuela Zanni,&nbsp;Maddalena Lettieri,&nbsp;Paolo Rivela,&nbsp;Francesco Zallio,&nbsp;Marco Ladetto","doi":"10.1515/jbcpp-2023-0051","DOIUrl":"https://doi.org/10.1515/jbcpp-2023-0051","url":null,"abstract":"<p><strong>Objectives: </strong>The use of Bruton's tyrosine kinase (BTK) inhibitors has changed the clinical history of patients with chronic lymphocytic leukemia (CLL) in both naïve and relapsed/refractory settings. \"Accelerated\" chronic lymphocytic leukemia (a-CLL) is a relatively rare form of CLL representing less than 1 % of all CLL cases. a-CLL patients usually have a more aggressive course and a reduced overall survival was reported with conventional chemo-immunotherapy approaches.</p><p><strong>Methods: </strong>The role of Bruton Tyrosine Kinase-inhibitor, ibrutinib, in a-CLL is well established with encouraging preliminary results.</p><p><strong>Results: </strong>We report a case of a-CLL-treated first-line with second-generation BTKi, acalabrutinib with a prompt clinical response. As known, it is the first literature report on acalabrutinib in a-CLL highlighting the role of second-generation BTKi also in this high-risk setting.</p><p><strong>Conclusions: </strong>Target therapies (Bruton Kinase inhibitors and Bcl2 inhibitors) have improved the therapeutic landscape of CLL. The availability of therapeutic targets requires greater diagnostic accuracy to choose the most appropriate therapy for each patient.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 3","pages":"401-404"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9472880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A hypothesis that Notopterol may be effective in COVID-19 via JAK/STAT and other signaling pathways. Notopterol可能通过JAK/STAT和其他信号通路对COVID-19有效的假设。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 DOI: 10.1515/jbcpp-2022-0028
Fereshteh Nazari-Khanamiri, Morteza Ghasemnejad-Berenji

COVID-19 is a rapidly spreading disease, causing a global pandemic. It is circulating in multiple countries and causing a series of respiratory infections. Due to the uncertain safety and efficacy of the vaccines and lack of specific medicines, it's important to investigate new pharmacological procedures and find out new drugs that help us eradicate this pandemic. We suggest the hypothesis that Notopterol (NOT), the main Secondary metabolite of Notopterygium incisum Ting ex H.T (a common Chinese medicinal herb), may have the potential benefits on SARS-CoV2 infection for this reasons: (a) NOT exhibits anti-inflammatory, anticancer, and anti-angiogenic properties, (b) NOT indicates a significant reduction in cytokines and chemokines releasing including TNFa, IL-6, interferon-γ, which may decrease COVID-19 cytokine storm (c) NOT can suppress the expression of genes which leads to inflammation via Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling pathway. It is exactly acting like tocilizumab, (an approved drug against COVID-19) and (d) Notopterygium incisum has antiviral activity against influenza virus, it can reduce the viral-induced oxidative stress. By these explanations, it is hopeful that NOT may be effective in COVID-19 infections which needs further investigations to examine Notopterol as a beneficial agent against the SARS-CoV2 infection.

COVID-19是一种迅速传播的疾病,会导致全球大流行。它正在多个国家传播,并引起一系列呼吸道感染。由于疫苗的安全性和有效性不确定以及缺乏特异性药物,研究新的药理学程序并找到帮助我们根除这种大流行的新药非常重要。因此,我们提出notoptergium incisum Ting ex H.T(一种常见的中草药)的主要次级代谢物Notopterol (NOT)可能对SARS-CoV2感染有潜在的益处:(a) NOT具有抗炎、抗癌和抗血管生成特性,(b) NOT表明细胞因子和趋化因子释放显著减少,包括TNFa、IL-6、干扰素-γ,这可能会降低COVID-19细胞因子风暴(c) NOT可以抑制通过Janus激酶/信号转导和转录激活因子(JAK-STAT)信号通路导致炎症的基因表达。它的作用与托珠单抗(一种被批准用于治疗COVID-19的药物)完全相同,并且(d)切牙nottopterygium对流感病毒具有抗病毒活性,它可以减少病毒诱导的氧化应激。通过这些解释,NOT可能对COVID-19感染有效,但需要进一步研究来检验诺托特罗是否对SARS-CoV2感染有益。
{"title":"A hypothesis that Notopterol may be effective in COVID-19 via JAK/STAT and other signaling pathways.","authors":"Fereshteh Nazari-Khanamiri,&nbsp;Morteza Ghasemnejad-Berenji","doi":"10.1515/jbcpp-2022-0028","DOIUrl":"https://doi.org/10.1515/jbcpp-2022-0028","url":null,"abstract":"<p><p>COVID-19 is a rapidly spreading disease, causing a global pandemic. It is circulating in multiple countries and causing a series of respiratory infections. Due to the uncertain safety and efficacy of the vaccines and lack of specific medicines, it's important to investigate new pharmacological procedures and find out new drugs that help us eradicate this pandemic. We suggest the hypothesis that Notopterol (NOT), the main Secondary metabolite of Notopterygium incisum Ting ex H.T (a common Chinese medicinal herb), may have the potential benefits on SARS-CoV2 infection for this reasons: (a) NOT exhibits anti-inflammatory, anticancer, and anti-angiogenic properties, (b) NOT indicates a significant reduction in cytokines and chemokines releasing including TNFa, IL-6, interferon-γ, which may decrease COVID-19 cytokine storm (c) NOT can suppress the expression of genes which leads to inflammation via Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling pathway. It is exactly acting like tocilizumab, (an approved drug against COVID-19) and (d) Notopterygium incisum has antiviral activity against influenza virus, it can reduce the viral-induced oxidative stress. By these explanations, it is hopeful that NOT may be effective in COVID-19 infections which needs further investigations to examine Notopterol as a beneficial agent against the SARS-CoV2 infection.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 3","pages":"405-407"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
A randomized controlled trial to evaluate the efficacy of electrical vestibular nerve stimulation (VeNS), compared to a sham control for the management of sleep in young adults. 一项评估前庭神经电刺激(VeNS)的有效性的随机对照试验,与假对照相比,用于管理年轻人的睡眠。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 DOI: 10.1515/jbcpp-2023-0036
Sai Sailesh Kumar Goothy, Rajagopalan Vijayaraghavan, Hirok Chakraborty

Objectives: Preliminary research suggests that electrical vestibular nerve stimulation (VeNS) may improve sleep outcomes by influencing the hypothalamus and brainstem nuclei involved in regulating the circadian rhythm and wakefulness. This randomised, sham-controlled trial aimed to assess the effectiveness of VeNS on insomnia in young adults.

Methods: Eighty adults aged 18-24 years were randomly allocated to the intervention (n=40) and control groups (n=40). The intervention group was provided with 30 min per day of VeNS with five sessions weekly for four weeks, while the control group received sham stimulation for the same period. Baseline Insomnia Sleep Index (ISI) scores were recorded weekly. At baseline and at day 28, questionnaires to evaluate emotional states of depression, anxiety and stress, and quality of life (QoL) were completed. The primary outcome was change in ISI with comparison between baseline and day 28.

Results: The VeNS group significantly reduced their mean ISI score after 7 days usage (p<0.001). At day 28 it was found that mean ISI scores had reduced from 19 to 11 in the VeNS group, and from 19 to 18 in the sham group, and the difference between the groups was significant (p<0.001). Moreover, application of VeNS appeared to significantly improve emotional state and QoL outcomes.

Conclusions: This trial demonstrates that regular VeNS usage over four weeks leads to a clinically meaningful decrease in ISI scores in young adults with insomnia. VeNS may have potential as a drug-free and non-invasive therapy to improve sleep outcomes by positively influencing the hypothalamic and brainstem nuclei.

目的:初步研究表明,前庭神经电刺激(VeNS)可能通过影响参与调节昼夜节律和觉醒的下丘脑和脑干核来改善睡眠结果。这项随机、假对照试验旨在评估VeNS对年轻人失眠的有效性。方法:80名18 ~ 24岁的成年人随机分为干预组(n=40)和对照组(n=40)。干预组每天进行30分钟的VeNS,每周5次,持续4周,对照组接受相同时间的假刺激。每周记录基线失眠睡眠指数(ISI)评分。在基线和第28天,完成抑郁、焦虑和压力情绪状态以及生活质量(QoL)的问卷调查。主要结局是ISI的变化与基线和第28天的比较。结果:VeNS组在使用7天后显著降低了他们的平均ISI评分(p结论:本试验表明,在4周内定期使用VeNS会导致患有失眠症的年轻成年人ISI评分有临床意义的下降。VeNS可能有潜力作为一种无药物和非侵入性治疗,通过积极影响下丘脑和脑干核来改善睡眠结果。
{"title":"A randomized controlled trial to evaluate the efficacy of electrical vestibular nerve stimulation (VeNS), compared to a sham control for the management of sleep in young adults.","authors":"Sai Sailesh Kumar Goothy,&nbsp;Rajagopalan Vijayaraghavan,&nbsp;Hirok Chakraborty","doi":"10.1515/jbcpp-2023-0036","DOIUrl":"https://doi.org/10.1515/jbcpp-2023-0036","url":null,"abstract":"<p><strong>Objectives: </strong>Preliminary research suggests that electrical vestibular nerve stimulation (VeNS) may improve sleep outcomes by influencing the hypothalamus and brainstem nuclei involved in regulating the circadian rhythm and wakefulness. This randomised, sham-controlled trial aimed to assess the effectiveness of VeNS on insomnia in young adults.</p><p><strong>Methods: </strong>Eighty adults aged 18-24 years were randomly allocated to the intervention (n=40) and control groups (n=40). The intervention group was provided with 30 min per day of VeNS with five sessions weekly for four weeks, while the control group received sham stimulation for the same period. Baseline Insomnia Sleep Index (ISI) scores were recorded weekly. At baseline and at day 28, questionnaires to evaluate emotional states of depression, anxiety and stress, and quality of life (QoL) were completed. The primary outcome was change in ISI with comparison between baseline and day 28.</p><p><strong>Results: </strong>The VeNS group significantly reduced their mean ISI score after 7 days usage (p<0.001). At day 28 it was found that mean ISI scores had reduced from 19 to 11 in the VeNS group, and from 19 to 18 in the sham group, and the difference between the groups was significant (p<0.001). Moreover, application of VeNS appeared to significantly improve emotional state and QoL outcomes.</p><p><strong>Conclusions: </strong>This trial demonstrates that regular VeNS usage over four weeks leads to a clinically meaningful decrease in ISI scores in young adults with insomnia. VeNS may have potential as a drug-free and non-invasive therapy to improve sleep outcomes by positively influencing the hypothalamic and brainstem nuclei.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 3","pages":"391-399"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9478221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and management of uterine fibroids: current trends and future strategies. 子宫肌瘤的诊断和治疗:目前的趋势和未来的策略。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 DOI: 10.1515/jbcpp-2022-0219
Azaz Ahmad, Manoj Kumar, Nihar Ranjan Bhoi, Badruddeen, Juber Akhtar, Mohammad Irfan Khan, Mohd Ajmal, Mohammad Ahmad

Uterine fibroids (UFs), leiomyomas or myomas, are a type of malignancy that affects the smooth muscle of the uterus, and it is most commonly detected in women of reproductive age. Uterine fibroids are benign monoclonal growths that emerge from uterine smooth muscle cells (myometrium) as well as fibroblasts. Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods. Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation. It is also associated with reproductive issues like impaired fertility, conceiving complications, and adverse obstetric outcomes. It is the leading cause of gynaecological hospitalisation in the American subcontinent and a common reason for the hysterectomy. Twenty-five percent of the reproductive women experience the symptoms of uterine fibroids, and among them, around 25% require hospitalization due to the severity of the disease. The frequency of the disease remains underestimated as many women stay asymptomatic and symptoms appear gradually; therefore, the condition remains undiagnosed. The exact frequency of uterine fibroids varies depending on the diagnosis, and the population investigated; nonetheless, the incidence of uterine fibroids in reproductive women ranges from 5.4 percent to 77 percent. The uterine fibroid treatment included painkillers, supplementation with iron, vitamin D3, birth control, hormone therapy, gonadotropin-releasing hormone (GnRH) agonists, drugs modulating the estrogen receptors, and surgical removal of the fibroids. However, more research needed at the level of gene to get a keen insight and treat the disease efficiently.

子宫肌瘤(UFs),平滑肌瘤或肌瘤,是一种影响子宫平滑肌的恶性肿瘤,最常见于育龄妇女。子宫肌瘤是良性的单克隆生长,出现在子宫平滑肌细胞(肌层)和成纤维细胞。子宫肌瘤的症状包括月经异常出血,导致贫血、疲劳、慢性阴道分泌物和经期疼痛。其他症状包括腹部突出、性交时疼痛、膀胱/肠道功能障碍导致尿失禁/潴留、疼痛和便秘。它还与生殖问题有关,如生育能力受损、妊娠并发症和不良产科结果。它是美国次大陆妇科住院的主要原因,也是子宫切除术的常见原因。25%的育龄妇女会出现子宫肌瘤的症状,其中约25%因病情严重需要住院治疗。该病的发病率仍然被低估,因为许多妇女没有症状,症状逐渐出现;因此,这种情况仍未得到诊断。子宫肌瘤的确切频率因诊断和调查人群而异;尽管如此,子宫肌瘤在育龄妇女中的发病率从5.4%到77%不等。子宫肌瘤的治疗包括止痛药、补充铁、维生素D3、节育、激素治疗、促性腺激素释放激素(GnRH)激动剂、调节雌激素受体的药物和手术切除肌瘤。然而,需要在基因水平上进行更多的研究,以获得敏锐的洞察力和有效的治疗疾病。
{"title":"Diagnosis and management of uterine fibroids: current trends and future strategies.","authors":"Azaz Ahmad,&nbsp;Manoj Kumar,&nbsp;Nihar Ranjan Bhoi,&nbsp;Badruddeen,&nbsp;Juber Akhtar,&nbsp;Mohammad Irfan Khan,&nbsp;Mohd Ajmal,&nbsp;Mohammad Ahmad","doi":"10.1515/jbcpp-2022-0219","DOIUrl":"https://doi.org/10.1515/jbcpp-2022-0219","url":null,"abstract":"<p><p>Uterine fibroids (UFs), leiomyomas or myomas, are a type of malignancy that affects the smooth muscle of the uterus, and it is most commonly detected in women of reproductive age. Uterine fibroids are benign monoclonal growths that emerge from uterine smooth muscle cells (myometrium) as well as fibroblasts. Uterine fibroid symptoms include abnormal menstrual bleeding leading to anaemia, tiredness, chronic vaginal discharge, and pain during periods. Other symptoms include protrusion of the abdomen, pain during intercourse, dysfunctions of bladder/bowel leading to urinary incontinence/retention, pain, and constipation. It is also associated with reproductive issues like impaired fertility, conceiving complications, and adverse obstetric outcomes. It is the leading cause of gynaecological hospitalisation in the American subcontinent and a common reason for the hysterectomy. Twenty-five percent of the reproductive women experience the symptoms of uterine fibroids, and among them, around 25% require hospitalization due to the severity of the disease. The frequency of the disease remains underestimated as many women stay asymptomatic and symptoms appear gradually; therefore, the condition remains undiagnosed. The exact frequency of uterine fibroids varies depending on the diagnosis, and the population investigated; nonetheless, the incidence of uterine fibroids in reproductive women ranges from 5.4 percent to 77 percent. The uterine fibroid treatment included painkillers, supplementation with iron, vitamin D3, birth control, hormone therapy, gonadotropin-releasing hormone (GnRH) agonists, drugs modulating the estrogen receptors, and surgical removal of the fibroids. However, more research needed at the level of gene to get a keen insight and treat the disease efficiently.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 3","pages":"291-310"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9843931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Antioxidant activity in off and on-pump coronary artery bypass grafting and valve replacement surgery. 无泵和无泵冠状动脉旁路移植术和瓣膜置换术的抗氧化活性。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 DOI: 10.1515/jbcpp-2022-0244
Ali Azari, Vafa Baradaran Rahimi, Zahra Moravvej, Amir Ali Rahsepar, Majid Ghayour-Mobarhan, Maryam Salehi, Leila Bigdelu

Objectives: Cardiac surgeries initiate oxidative stress, increasing organ dysfunction development and mortality. The present study investigated the superoxide dismutase (SOD) activity, as an antioxidant enzyme, in patients undergoing coronary artery bypass (CABG) and heart valve replacement surgeries.

Methods: A prospective study was performed on patients with proven coronary artery disease (CAD) or valvular heart disease (VHD) candidates for on- or off-pump CABG and valve replacement surgery. Serum SOD activity was measured preoperatively, at 24 h postoperatively, and at the time of discharge. In addition, echocardiography was performed before surgery and at discharge.

Results: A total of 48, 51, and 47 patients were enrolled in the on-pump, off-pump CABG, and valve replacement groups, respectively. Baseline serum SOD activity showed no significant association with BMI, age, and blood pressure in either CAD or VHD patients. The SOD values decreased at the 24 h postoperative time and then increased at the time of discharge in all groups, except for a slight decrease in the on-pump group. The changes in serum SOD values were not significantly different for the three surgical groups.

Conclusions: The serum SOD activities fell significantly after CABG and valve replacement surgery. Further investigation is emphasized for the role of SOD in oxidative stress after cardiac surgery.

目的:心脏手术引发氧化应激,增加器官功能障碍的发展和死亡率。本研究探讨了作为抗氧化酶的超氧化物歧化酶(SOD)在冠状动脉搭桥术(CABG)和心脏瓣膜置换术患者中的活性。方法:一项前瞻性研究对已证实的冠状动脉疾病(CAD)或瓣膜性心脏病(VHD)患者进行了开泵或不开泵CABG和瓣膜置换术。术前、术后24 h及出院时测定血清SOD活性。此外,术前和出院时进行超声心动图检查。结果:有泵、无泵CABG和瓣膜置换术组分别有48例、51例和47例患者入组。在CAD或VHD患者中,基线血清SOD活性显示与BMI、年龄和血压无显著关联。除无泵组SOD值略有下降外,其余各组术后24 h均呈下降趋势,出院时均呈上升趋势。三组患者血清SOD值变化无显著性差异。结论:CABG和瓣膜置换术后血清SOD活性明显下降。进一步研究SOD在心脏手术后氧化应激中的作用。
{"title":"Antioxidant activity in off and on-pump coronary artery bypass grafting and valve replacement surgery.","authors":"Ali Azari,&nbsp;Vafa Baradaran Rahimi,&nbsp;Zahra Moravvej,&nbsp;Amir Ali Rahsepar,&nbsp;Majid Ghayour-Mobarhan,&nbsp;Maryam Salehi,&nbsp;Leila Bigdelu","doi":"10.1515/jbcpp-2022-0244","DOIUrl":"https://doi.org/10.1515/jbcpp-2022-0244","url":null,"abstract":"<p><strong>Objectives: </strong>Cardiac surgeries initiate oxidative stress, increasing organ dysfunction development and mortality. The present study investigated the superoxide dismutase (SOD) activity, as an antioxidant enzyme, in patients undergoing coronary artery bypass (CABG) and heart valve replacement surgeries.</p><p><strong>Methods: </strong>A prospective study was performed on patients with proven coronary artery disease (CAD) or valvular heart disease (VHD) candidates for on- or off-pump CABG and valve replacement surgery. Serum SOD activity was measured preoperatively, at 24 h postoperatively, and at the time of discharge. In addition, echocardiography was performed before surgery and at discharge.</p><p><strong>Results: </strong>A total of 48, 51, and 47 patients were enrolled in the on-pump, off-pump CABG, and valve replacement groups, respectively. Baseline serum SOD activity showed no significant association with BMI, age, and blood pressure in either CAD or VHD patients. The SOD values decreased at the 24 h postoperative time and then increased at the time of discharge in all groups, except for a slight decrease in the on-pump group. The changes in serum SOD values were not significantly different for the three surgical groups.</p><p><strong>Conclusions: </strong>The serum SOD activities fell significantly after CABG and valve replacement surgery. Further investigation is emphasized for the role of SOD in oxidative stress after cardiac surgery.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 3","pages":"365-370"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9471824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of cardiac autonomic function across complete glycaemic spectrum. 全血糖谱心脏自主神经功能的比较。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 DOI: 10.1515/jbcpp-2022-0053
Rajathi Rajendran, Vivek Kumar Sharma, Kolar Vishwanath Vinod, Ramesh Ananthakrishnan, Hanumanthappa Nandeesha, Senthil Kumar Subramanian

Objectives: Autonomic imbalance is attributed as key mechanism altering metabolic regulation in diabetes mellitus. In view of controversial reports on autonomic function in FDRD and prediabetes, we aimed to assess and compare the autonomic function across the complete glycaemic spectrum in Indian population.

Methods: Short term heart rate variability and cardiac autonomic reactivity tests - blood pressure and heart rate response to orthostatic tolerance and deep breathing exercise, and diastolic response to isometric handgrip exercise were recorded in normoglycemic apparently healthy individual, normoglycemic first degree relatives of diabetes, prediabetes and diabetes individuals.

Results: Resting heart rate is significantly higher in FDRD, prediabetes and diabetes as compared to controls (control < FDRD = prediabetes = diabetes). Total power, LF power (control < FDRD < prediabetes = diabetes) and HF power (control < FDRD < prediabetes < diabetes) decreased along the glycaemic spectrum. Time-domain variables of HRV (SDNN, RMSSD, NN50, pNN50) were reduced as we move along the glycaemic spectrum (control < FDRD < prediabetes = diabetes). Cardiac autonomic function reactivity parameters such as 30:15 ratio and E:I ratio are decreased in prediabetes and diabetes group as compared to control and FDRD group (control = FDRD < prediabetes = diabetes). Diastolic response to isometric hand grip increases along the glycaemic spectrum starting from FDRD (control < FDRD < prediabetes = diabetes).

Conclusions: Autonomic dysfunction is observed even in first degree relatives of diabetes. Autonomic dysfunction increases as we move along the glycaemic spectrum (control < FDRD < prediabetes < diabetes).

目的:自主神经失衡被认为是改变糖尿病代谢调节的重要机制。鉴于FDRD和前驱糖尿病患者自主神经功能有争议的报道,我们旨在评估和比较印度人群在整个血糖谱中的自主神经功能。方法:对血糖正常的明显健康个体、血糖正常的糖尿病一级亲属、糖尿病前期和糖尿病患者进行短期心率变异性和心脏自主反应试验,记录直立耐力和深呼吸运动时的血压和心率反应,以及等长握力运动时的舒张反应。结果:FDRD、前驱糖尿病和糖尿病患者的静息心率明显高于对照组(对照)结论:即使在糖尿病的一级亲属中也观察到自主神经功能障碍。当我们沿着血糖谱(控制)移动时,自主神经功能障碍会增加
{"title":"Comparison of cardiac autonomic function across complete glycaemic spectrum.","authors":"Rajathi Rajendran,&nbsp;Vivek Kumar Sharma,&nbsp;Kolar Vishwanath Vinod,&nbsp;Ramesh Ananthakrishnan,&nbsp;Hanumanthappa Nandeesha,&nbsp;Senthil Kumar Subramanian","doi":"10.1515/jbcpp-2022-0053","DOIUrl":"https://doi.org/10.1515/jbcpp-2022-0053","url":null,"abstract":"<p><strong>Objectives: </strong>Autonomic imbalance is attributed as key mechanism altering metabolic regulation in diabetes mellitus. In view of controversial reports on autonomic function in FDRD and prediabetes, we aimed to assess and compare the autonomic function across the complete glycaemic spectrum in Indian population.</p><p><strong>Methods: </strong>Short term heart rate variability and cardiac autonomic reactivity tests - blood pressure and heart rate response to orthostatic tolerance and deep breathing exercise, and diastolic response to isometric handgrip exercise were recorded in normoglycemic apparently healthy individual, normoglycemic first degree relatives of diabetes, prediabetes and diabetes individuals.</p><p><strong>Results: </strong>Resting heart rate is significantly higher in FDRD, prediabetes and diabetes as compared to controls (control < FDRD = prediabetes = diabetes). Total power, LF power (control < FDRD < prediabetes = diabetes) and HF power (control < FDRD < prediabetes < diabetes) decreased along the glycaemic spectrum. Time-domain variables of HRV (SDNN, RMSSD, NN50, pNN50) were reduced as we move along the glycaemic spectrum (control < FDRD < prediabetes = diabetes). Cardiac autonomic function reactivity parameters such as 30:15 ratio and E:I ratio are decreased in prediabetes and diabetes group as compared to control and FDRD group (control = FDRD < prediabetes = diabetes). Diastolic response to isometric hand grip increases along the glycaemic spectrum starting from FDRD (control < FDRD < prediabetes = diabetes).</p><p><strong>Conclusions: </strong>Autonomic dysfunction is observed even in first degree relatives of diabetes. Autonomic dysfunction increases as we move along the glycaemic spectrum (control < FDRD < prediabetes < diabetes).</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 3","pages":"329-336"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9476042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anti-ageing effects of FDA-approved medicines: a focused review. fda批准药物的抗衰老作用:重点综述。
Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-05-01 DOI: 10.1515/jbcpp-2022-0242
Koranit Thanapairoje, Supanut Junsiritrakhoon, Surasak Wichaiyo, Mohd Azuraidi Osman, Wasu Supharattanasitthi

Ageing is the process generated by senescent cells, free radicals, inflammation and other relevant factors. Ageing contributes to age-related diseases that affect the quality of life. People are interested in anti-ageing intervention and many scientists attempt to search for anti-ageing medicines. This review focused on describing in vivo anti-ageing activity of US-FDA-approved drugs and found that alogliptin, canagliflozin and metformin might produce anti-ageing activity via AMPK activation. Rapamycin and canagliflozin are capable to inhibit mTOR to promote lifespan. Atracurium, carnitine and statins act as DAF-16 activators, which potentially contribute to anti-ageing activity. Hydralazine, lisinopril, rosiglitazone and zidovudine may help stabilize genomic integrity to prolong life expectancy. Other indirect mechanisms, including insulin-lowering effect by acarbose and calcium channel blocking activity by verapamil may also promote longevity. Interestingly, some drugs (i.e., canagliflozin, metformin, rapamycin and acarbose) are likely to demonstrate a lifespan-promoting effect predominantly in male animals. These pre-clinical data might provide mechanistic and phenotypic perspectives to better understand the targets of anti-ageing interventions.

衰老是由衰老细胞、自由基、炎症和其他相关因素产生的过程。老龄化会导致影响生活质量的与年龄有关的疾病。人们对抗衰老干预很感兴趣,许多科学家试图寻找抗衰老药物。本综述重点描述了美国fda批准的药物的体内抗衰老活性,发现阿格列汀、卡格列清和二甲双胍可能通过激活AMPK产生抗衰老活性。雷帕霉素和卡格列净能够抑制mTOR以延长寿命。阿曲库铵、肉碱和他汀类药物作为DAF-16激活剂,具有潜在的抗衰老活性。海氮嗪、赖诺普利、罗格列酮和齐多夫定可能有助于稳定基因组完整性,延长预期寿命。其他间接机制,包括阿卡波糖的胰岛素降低作用和维拉帕米的钙通道阻断活性也可能促进长寿。有趣的是,一些药物(如卡格列净、二甲双胍、雷帕霉素和阿卡波糖)可能主要在雄性动物身上表现出延长寿命的效果。这些临床前数据可能为更好地理解抗衰老干预的目标提供机制和表型视角。
{"title":"Anti-ageing effects of FDA-approved medicines: a focused review.","authors":"Koranit Thanapairoje,&nbsp;Supanut Junsiritrakhoon,&nbsp;Surasak Wichaiyo,&nbsp;Mohd Azuraidi Osman,&nbsp;Wasu Supharattanasitthi","doi":"10.1515/jbcpp-2022-0242","DOIUrl":"https://doi.org/10.1515/jbcpp-2022-0242","url":null,"abstract":"<p><p>Ageing is the process generated by senescent cells, free radicals, inflammation and other relevant factors. Ageing contributes to age-related diseases that affect the quality of life. People are interested in anti-ageing intervention and many scientists attempt to search for anti-ageing medicines. This review focused on describing <i>in vivo</i> anti-ageing activity of US-FDA-approved drugs and found that alogliptin, canagliflozin and metformin might produce anti-ageing activity via AMPK activation. Rapamycin and canagliflozin are capable to inhibit mTOR to promote lifespan. Atracurium, carnitine and statins act as DAF-16 activators, which potentially contribute to anti-ageing activity. Hydralazine, lisinopril, rosiglitazone and zidovudine may help stabilize genomic integrity to prolong life expectancy. Other indirect mechanisms, including insulin-lowering effect by acarbose and calcium channel blocking activity by verapamil may also promote longevity. Interestingly, some drugs (i.e., canagliflozin, metformin, rapamycin and acarbose) are likely to demonstrate a lifespan-promoting effect predominantly in male animals. These pre-clinical data might provide mechanistic and phenotypic perspectives to better understand the targets of anti-ageing interventions.</p>","PeriodicalId":15352,"journal":{"name":"Journal of Basic and Clinical Physiology and Pharmacology","volume":"34 3","pages":"277-289"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9472224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Basic and Clinical Physiology and Pharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1